



Contacts

Media: Deanne Eagle, Cameron Associates – 917-837-5866

Bill Wells, Guided Therapeutics – 770-242-8723

Investors: Alison Ziegler, Cameron Associates – 212-554-5469

Study Indicates Guided Therapeutics' LuViva Advanced Cervical Scan Has Potential to Detect Disease Early and Reduce Unnecessary Biopsies for Women

WASHINGTON, D.C. (May 3, 2011) – As many as one million American women could avoid painful and unnecessary biopsies of the cervix and another estimated 170,000 could potentially be identified with cervical disease up to two years earlier, if technology developed by [Guided Therapeutics, Inc.](#) (OTCBB & OTCQB: GTHP) was widely used, according to a presentation made by Dr. Leo B. Twiggs, professor in the Department of Obstetrics and Gynecology at the University of Miami, Miller School of Medicine, to The American College of Obstetricians and Gynecologists (ACOG) Annual Clinical Meeting. The presentation was entitled *Study Results of a New Test for Cervical Dysplasia: Potential Impact on Patient Management*.

Guided Therapeutics' LuViva Advanced Cervical Scan, which is under U.S. Food and Drug Administration (FDA) premarket approval review, uses light to search for markers of dysplasia, or cervical disease, which may lead to cancer. More than 1,607 women were tested by investigational devices for the pivotal clinical trial necessary for an FDA review.

“We believe that the results, presented by Dr. Twiggs at ACOG, are extremely compelling and demonstrate the potential positive impact the technology could have on women’s health,” said Mark L. Faupel, Ph.D., CEO and President of Guided Therapeutics, Inc. “As a principal investigator in the clinical trial, Dr. Twiggs is a visionary in this field and was instrumental in the development of the technology.”

The LuViva technology, which consists of a base unit and single-patient-use calibration disposable, scans the cervix with light to identify cancer and pre-cancer painlessly and non-invasively. Guided Therapeutics' patented biophotonic technology is able to distinguish between normal and diseased tissue by detecting biochemical and morphological changes at the cellular level. Unlike Pap or HPV tests, the LuViva test would not require laboratory analysis or a tissue sample, is designed to provide results immediately and eliminate costly unnecessary testing.

For more details on the study and results presented by Dr. Twiggs, visit www.guidedinc.com.

About ACOG

Founded in 1951 in Chicago, Illinois, ACOG has over 52,000 members and is the nation's leading group of professionals providing health care for women. Now based in Washington, D.C., it is a private, voluntary, nonprofit membership organization. For more information, visit www.acog.org.

About Guided Therapeutics

Guided Therapeutics, Inc. (OTCBB & OTCQB: GTHP) is developing a rapid and painless testing platform for the early detection of disease based on its patented biophotonic technology that utilizes light to detect disease at the cellular level. The company's first planned product is the LuViva™ Advance Cervical Scan, a non-invasive device used to detect cervical disease instantly and at the point of care. In a multi-center clinical trial, with women at risk for cervical disease, the technology was able to detect cervical cancer up to two years earlier than conventional modalities, according to published reports. Guided Therapeutics has also entered into a partnership with Konica Minolta Opto to develop a non-invasive test for Barrett's Esophagus using the technology platform. For more information, visit: www.guidedinc.com.

The Guided Therapeutics LuViva Advanced Cervical Scan is an investigational device and is limited by federal law to investigational use.

The LuViva mark, LuViva and wave logo, and "Early detection, better outcomes" are trademarks owned by Guided Therapeutics, Inc.

"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995. A number of the matters and subject areas discussed in this news release that are not historical or current facts deal with potential future circumstances and developments. The discussion of such matters and subject areas is qualified by the inherent risks and uncertainties surrounding future expectations generally and also may materially differ from Guided Therapeutics' actual future experience involving any of or more of such matters and subject areas. Such risks and uncertainties include: the early stage of products in development, the uncertainty of market acceptance of products, the uncertainty of development or effectiveness of distribution channels, the intense competition in the medical device industry, the uncertainty of capital to develop products, the uncertainty of regulatory approval of products, dependence on licensed intellectual property, as well as those that are more fully described from time to time under the heading "Risk Factors" in Guided Therapeutics' reports filed with the SEC, including Guided Therapeutics' Annual Report on Form 10-K for the fiscal year ended December 31, 2010.

###